Zymeworks Inc. is a privately held biotechnology company committed to developing best-in-class protein therapeutics for the treatment of cancer.
Author: Global Cancer Consortium
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
OncoSec Medical is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
This week, we respond to a recent Wall Street Journal article documenting immunotherapy as a new treatment for Cancer. We tell you what companies they missed. OneMedRadio brings you management interviews with Synthetic Biologics, Pluristem, Nanoviricides, and Biovest. We also interviewed Gerry DiFiore, partner at Reed Smith, sponsor of our recent OneMedForum NY 2012 kick off reception in New York City. Gearing up for our third annual trans-Atlantic conference in New York, we have many new interesting companies slated to present. Stay tuned for feature articles highlighting these disruptive technologies. And don’t forget to register to be present July 12th…
On June 1, more than 25,000 cancer specialists will come together at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. With ASCO hours away, we look at some small biotech companies making headway in cancer treatment.
Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.